These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30119171)

  • 1. Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.
    Jiang X; Ganesan P; Rengarajan T; Choi DK; Arulselvan P
    Biomed Pharmacother; 2018 Oct; 106():1052-1062. PubMed ID: 30119171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review.
    Bjørklund G; Dadar M; Anderson G; Chirumbolo S; Maes M
    Pharmacol Res; 2020 Nov; 161():105065. PubMed ID: 32652199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microglia mediated neuroinflammation - signaling regulation and therapeutic considerations with special reference to some natural compounds.
    Yao YY; Ling EA; Lu D
    Histol Histopathol; 2020 Nov; 35(11):1229-1250. PubMed ID: 32662061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators.
    Jayaram S; Krishnamurthy PT
    Neurochem Int; 2021 May; 145():105014. PubMed ID: 33689805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.
    Angelopoulou E; Paudel YN; Shaikh MF; Piperi C
    Pharmacol Res; 2020 Aug; 158():104930. PubMed ID: 32445958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease.
    Lashgari NA; Roudsari NM; Momtaz S; Sathyapalan T; Abdolghaffari AH; Sahebkar A
    J Neuroimmunol; 2021 Dec; 361():577758. PubMed ID: 34739911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases.
    Zanforlin E; Zagotto G; Ribaudo G
    ACS Chem Neurosci; 2017 Nov; 8(11):2356-2368. PubMed ID: 28862431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
    Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Yang L; Mao K; Yu H; Chen J
    J Neuroimmune Pharmacol; 2020 Dec; 15(4):830-837. PubMed ID: 32529463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glia as a turning point in the therapeutic strategy of Parkinson's disease.
    L' Episcopo F; Tirolo C; Testa N; Caniglia S; Morale MC; Marchetti B
    CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):349-72. PubMed ID: 20438439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
    Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
    Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases.
    Sandhu JK; Kulka M
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 inhibition in psoriatic arthritis.
    Boyd T; Kavanaugh A
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S119-23. PubMed ID: 26471234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory response in Parkinson's disease (Review).
    Yan J; Fu Q; Cheng L; Zhai M; Wu W; Huang L; Du G
    Mol Med Rep; 2014 Nov; 10(5):2223-33. PubMed ID: 25215472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroinflammation in Parkinson's disease and its potential as therapeutic target.
    Wang Q; Liu Y; Zhou J
    Transl Neurodegener; 2015; 4():19. PubMed ID: 26464797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway.
    Jing H; Wang S; Wang M; Fu W; Zhang C; Xu D
    PLoS One; 2017; 12(1):e0169560. PubMed ID: 28060896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of neuroinflammation: Role and therapeutic potential of TRPV1 in the neuro-immune axis.
    Kong WL; Peng YY; Peng BW
    Brain Behav Immun; 2017 Aug; 64():354-366. PubMed ID: 28342781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.
    De Miranda BR; Popichak KA; Hammond SL; Miller JA; Safe S; Tjalkens RB
    Toxicol Sci; 2015 Feb; 143(2):360-73. PubMed ID: 25406165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.